Navigation Links
Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
Date:6/11/2008

LONDON, June 11 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced that it has obtained regulatory approval from the South African Medicines Control Council (MCC) to initiate a Phase II study of MRX-4 in 105 patients suffering from allergic rhinitis (AR). The two-arm, randomized, multi-dose, double-blind, placebo-controlled study includes a steroid comparator arm.

The study will evaluate the safety, tolerability, and preliminary efficacy of intranasal MRX-4 in AR patients outside of allergy season as compared with both placebo and an intranasal steroid. An experimental multi-functional anti-inflammatory drug (MFAID), MRX-4 is a non-steroidal potential treatment for AR that was shown to be safe and well tolerated in a Phase I equivalent trial completed in Israel earlier this year.

"This study will provide valuable data regarding its potential in allergic rhinitis, including efficacy, tolerability and pharmacokinetic data," said Dr. Yuval Cohen, president of Morria. "We are excited to be taking this significant step toward testing a potentially safer, more effective, and more affordable treatment option for the significant commercial opportunity in the multi-billion dollar allergic rhinitis market".

ABOUT ALLERGIC RHINITIS

Allergic rhinitis is a common condition that affects nearly 59 million people in the United States (nearly 20 percent of the population) with a market of close to $4 billion. Allergic rhinitis is characterized by inflammation of the nasal membranes accompanied by symptoms that may include sneezing, nasal congestion, nasal itching and rhinorrhea.

ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel anti-inflammatory pharmaceuticals termed multi-functional anti-inflammatory drugs (MFAIDs). This class of drugs uniquely combine
'/>"/>

SOURCE Morria Biopharmaceuticals Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
2. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
3. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
5. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
6. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
7. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
8. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
9. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
10. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
11. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 20, 2015 Research ... addition of the "D-dimer Testing Market - ... and Forecast 2014 - 2022" report to ... in vitro diagnostics market is one of the ... be attributed to the improved health care awareness, ...
(Date:7/27/2015)... , July 17, 2015 Research and ... of the "G-Protein Coupled Receptors Market: Global ... 2014 - 2022" report to their offering. ... been segmented based on of assay type, therapeutic ... GPCRs market has been categorized into six major ...
(Date:7/27/2015)... , July 27, 2015 Bloomage BioTechnology ... announces a strategic cooperation with the South Korean BioTech ... a joint venture Medybloom to develop and promote Type ... China . Medytox, the Botulinum ... and is also the fourth company in the world ...
Breaking Medicine Technology:D-dimer Testing Market - Global Industry Analysis 2015 2D-dimer Testing Market - Global Industry Analysis 2015 3G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 2Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 2Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 3
(Date:7/27/2015)... ... 27, 2015 , ... Interactive health education is a highly ... Wound Care Advantage beta launched Luvo University, an online learning management ... learning paths allow for clinicians, physicians, hyperbaric technicians and non-clinical staff to get ...
(Date:7/27/2015)... ... July 27, 2015 , ... Writing Effective ... Aug. 13, 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/writingeffectivesops ... FDA investigators will look at during an inspection. Yet, in 2014, "inadequate ...
(Date:7/27/2015)... ... , ... In a piece published July 22 on LinkedIn’s Pulse, ... explained why people should not shy away from their own personal aspirations. The author ... and celebrate it for the modern wonder that it is.” This is a great ...
(Date:7/27/2015)... ... ... Looking to brush up on all the things you should be doing ... enhanced its Dental webpage with new materials, including user-friendly, educational videos, to help members ... to offering our 3.8 million members tools and resources to help them keep a ...
(Date:7/27/2015)... TX (PRWEB) , ... July 27, 2015 , ... North ... of 2015. , The center invites all those prospective joint-replacement patients, along with ... and Thursday of each month, with Monday classes (Aug 6, Sept 8 [Tue due ...
Breaking Medicine News(10 mins):Health News:Wound Care Advantage Launches Luvo University An Online Hub For Wound Care Education and Training 2Health News:Wound Care Advantage Launches Luvo University An Online Hub For Wound Care Education and Training 3Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 2Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 3Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 4Health News:Recent Op-Ed Defending Plastic Surgery Highlights the Personal Side of Cosmetic Procedures, says Beverly Hills Physicians 2Health News:Thinking about a Dental Check-up? Check out Horizon Blue Cross Blue Shield of New Jersey’s Enhanced Website for a Dental Download of Helpful Information 2Health News:North Central Surgical Center Hospital to Hold Joint Wellness Classes 2
... cases of bird flu, the chief state epidemiologist Gennady ... the sixth country where the deadly H5N1 bird flu virus ... outside eastern Asia. ,"I earnestly advise Russian citizens ... province of Agri and the city of Dogubayazit where the ...
... year. The need the organ, kidney is on the rise and ... all the organ transplantations done, kidney transplantation accounts for 64%. But ... the number of people who come forward to donate organs especially ... to undergo kidney transplants has widened to more than four years. ...
... Chief of the Specialty Hospital in the United States, ... a shot in the arm.//Specialty Hospitals thought of as ... was nipped in the bud, owing to vested interests ... The Wall Street Journal, has expressed disappointment at the ...
... can be detected years before the symptoms even appear, according ... the size of two parts of the brain, according to ... Those with a smaller hippocampus or amygdala are much more ... General Psychiatry. ,Both parts decline in size ...
... Alarming reports of AIDS patients being robbed off their pockets ... shift in the service based health care system, // believed ... ,Cai had no AIDS related symptoms when she was admitted ... she had, ensured prompt medical attention at the time of ...
... A considerable improvement in the oral feeding habits of ... 11 days following institution of feeding facilitating techniques. // ... been the use of a feeding tube. Prolonged use ... risk for development of gastroesophageal reflux. With the introduction ...
Cached Medicine News:Health News:Russia warns against travel to Turkey, Iran closes border 2Health News:AIDS Patients Deceived By Private Health Care System In China 2Health News:New Technique Enables Better Nursing Of Robin Sequence Infants 2
Rapid assay, results in 1 hours,Assay sensitivity of 1.14 ng/mL...
... IMMULITE 1000 assays are designed ... and IMMULITE 1000, continuous random ... simplicity in both design and ... found in a wide variety ...
... digital x-ray detectors from KUBTEC represents a ... 12 to 16 bit digital interface. The ... array sensor with pixel spacing down to ... low x-ray energies (10-50 kV) and an ...
... from KUBTEC is a dual capability system with ... representation of the specimen under test. While the ... images, the micro focus source also allows the ... standard 2D images. The 100 mm x 100 ...
Medicine Products: